Expansion Opportunity EpiVax recently expanded its Providence laboratory facilities, signaling capacity growth and potential for larger client programs or longer engagements in immunogenicity risk assessment and related services.

Strategic Acquisition SV Health Investors acquired EpiVax, indicating financial backing and potential for expanded go-to-market efforts, new service lines, or scaled collaborations with pharma and biotech partners.

CSO Leadership Recent appointments of Vibha Jawa as Chief Scientific Officer and ongoing immunogenicity leadership highlight a strengthened scientific roadmap, presenting opportunities to position new capabilities and high-impact projects to prospective clients.

Broad Capabilities EpiVax combines computational analyses, in vitro assays, and expert consulting across immunogenicity risk assessment, ISPRI Toolkit expansions, and personalized vaccine/cancer therapy collaborations, offering a comprehensive value proposition to pharma pipelines.

Market Position With a 25+ year track record in immunogenicity and a mid-market size profile, EpiVax is well suited for partnerships with startups and mid-cap biopharma seeking risk mitigation, regulatory support, and early-to-late stage development services.